search
Back to results

Extracorporeal Carbon Dioxide Removal for Acute Respiratory Distress Syndrome

Primary Purpose

Acute Respiratory Distress Syndrome, Lung Diseases

Status
Completed
Phase
Phase 3
Locations
Study Type
Interventional
Intervention
positive-pressure ventilation
extracorporeal membrane oxygenation (CO2 removal)
Sponsored by
Intermountain Health Care, Inc.
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Acute Respiratory Distress Syndrome

Eligibility Criteria

18 Years - 65 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Men and women with acute respiratory distress syndrome. Inclusion Criteria: ECMO ENTRY CRITERIA (PaO2 < 50 mm Hg -REPEATED THREE TIMES): Rapid entry: 2 hours at fraFIO2=1.00 and PEEP>5 cm H2O with PaCO2=30-45 mmHg Slow entry: 12 hours at fraction of inspired oxygen (FIO2)>0.60 and positive end-expiratory pressure (PEEP)>5 cm H2O with PaCO2=30-45 mmHg and right to Left shunt fraction >0.30 Exclusion Criteria: Contraindication to anti-coagulation (for example, gastrointestinal bleeding, recent cerebrovascular accident, or chronic bleeding disorder). Pw > 25 mm Hg (superseded by our screening criterion that Pw ~ 15 mm Hg). Mechanical ventilation >21. days. Severe chronic systemic disease or another clinical condition that, in itself,greatly limits survival; for example, Irreversible central nervous system disease Severe chronic pulmonary disease (forced expiratory volume in 1 second (FEV1)<1 L, FEV1/FVC(forced vital capacity) <0.3 of predicted, chronic PaCO2 >45 mm Hg, chest x-ray evidence of overinflation or interstitial infiltration, or previous hospitalization for chronic respiratory insufficiency) Total-body surface burns> 40% Rapidly fatal malignancy Chronic left ventricular failure Chronic renal failure (we required serum creatlnlne ~ 2 mg/dl or chronic dialysis therapy) Chronic liver failure (we required total serum bilirubin;?; 2 mg/dl) Immunosuppressed patients and patients with a positive human immu.. nodeficiency virus test

Sites / Locations

    Arms of the Study

    Arm 1

    Arm 2

    Arm Type

    Experimental

    Active Comparator

    Arm Label

    Extracorporeal membrane oxygenation (CO2 removal)

    Protocol Controlled positive-pressure vent

    Arm Description

    Detailed Electronic Protocol Controlled Extracorporeal CO2 Removal with reduced positive-pressure ventilation

    Detailed Electronic Protocol Controlled positive-pressure ventilation

    Outcomes

    Primary Outcome Measures

    Survival
    All deaths occurred within 30 days of enrollment

    Secondary Outcome Measures

    Hospital days
    ICU days

    Full Information

    First Posted
    October 27, 1999
    Last Updated
    March 4, 2018
    Sponsor
    Intermountain Health Care, Inc.
    Collaborators
    National Heart, Lung, and Blood Institute (NHLBI)
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT00000572
    Brief Title
    Extracorporeal Carbon Dioxide Removal for Acute Respiratory Distress Syndrome
    Official Title
    Extracorporeal Carbon Dioxide Removal for Acute Respiratory Distress Syndrome
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    March 2018
    Overall Recruitment Status
    Completed
    Study Start Date
    June 1987 (undefined)
    Primary Completion Date
    April 1991 (Actual)
    Study Completion Date
    January 1993 (Actual)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Principal Investigator
    Name of the Sponsor
    Intermountain Health Care, Inc.
    Collaborators
    National Heart, Lung, and Blood Institute (NHLBI)

    4. Oversight

    Data Monitoring Committee
    No

    5. Study Description

    Brief Summary
    To compare conventional therapy using low frequency positive pressure ventilation with extracorporeal CO2 removal for the treatment of adult respiratory distress syndrome (ARDS).
    Detailed Description
    BACKGROUND: It is estimated that at least 150,000 individuals die each year of adult respiratory distress syndrome. Treatment remains largely supportive. The National Heart, Lung, and Blood Institute (NHLBI) conducted the Extracorporeal Support for Respiratory Insufficiency (ECMO, Extracorporeal Membrane Oxygenation) trial from June 1974 through 1978. In ECMO, 90 patients were randomized to either extracorporeal membrane oxygenation plus conventional therapy or to conventional therapy. Survival rates were less than ten percent in both groups. The failure of the trial to demonstrate the superiority of ECMO over conventional ventilatory support resulted in the virtual elimination of the use of ECMO in clinical medicine. In the earlier NHLBI trial, ECMO was implemented with a veno-arterial shunt which approximated 90 percent of the baseline cardiac output. Ventilation of the lungs was continued with reduced function of inspiration oxygen. Thus, the lungs were deprived of the principle source of blood supply while continuously exposed to potentially injurious ventilatory pressures and gas composition. The present patient trial used a new form of therapy developed by Dr. Gattinoni and co-workers in Milan, Italy with the collaboration of Dr. Kolobow at the National Institutes of Health in Bethesda. The authors reported a 77 percent survival rate for the new therapy. In Step 1 of the new therapy, the patient was initially ventilated with pressure-controlled, inverted ratio ventilation. If the patient did not improve, Step 2 using extracorporeal perfusion was performed with a veno-venous shunt in contrast to a veno-arterial shunt. The veno-venous shunt preserved pulmonary blood flow whereas the veno-arterial shunt diminished it. Step 3 was reserved for those patients who did not meet the therapeutic criteria of Step 2. They underwent low frequency positive-pressure ventilation and extracorporeal CO2 removal involving veno-venous bypass via the internal jugular and femoral or bilateral saphenous veins. DESIGN NARRATIVE: Randomized, fixed sample. Patients were stratified by age (under and over 40 years) and by the presence or absence of trauma. Patients were assigned to conventional positive pressure ventilation therapy or to a three-step therapeutic program employing pressure-controlled-inverted-ratio-ventilation, continuous positive airway pressure, and low-frequency positive pressure ventilation-extracorporeal CO2 removal. The main outcome measure was survival at 30 days after randomization. Secondary outcome measures included hospital costs, physiologic data, length of hospital stay, and blood product consumption. Follow-up took place during the year after hospital discharge.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Acute Respiratory Distress Syndrome, Lung Diseases

    7. Study Design

    Primary Purpose
    Treatment
    Study Phase
    Phase 3
    Interventional Study Model
    Parallel Assignment
    Masking
    None (Open Label)
    Allocation
    Randomized
    Enrollment
    40 (Actual)

    8. Arms, Groups, and Interventions

    Arm Title
    Extracorporeal membrane oxygenation (CO2 removal)
    Arm Type
    Experimental
    Arm Description
    Detailed Electronic Protocol Controlled Extracorporeal CO2 Removal with reduced positive-pressure ventilation
    Arm Title
    Protocol Controlled positive-pressure vent
    Arm Type
    Active Comparator
    Arm Description
    Detailed Electronic Protocol Controlled positive-pressure ventilation
    Intervention Type
    Procedure
    Intervention Name(s)
    positive-pressure ventilation
    Intervention Description
    Detailed computer protocol controlled positive pressure ventilation
    Intervention Type
    Procedure
    Intervention Name(s)
    extracorporeal membrane oxygenation (CO2 removal)
    Intervention Description
    Detailed computer protocol controlled Extracorporeal CO2 Removal with reduced positive pressure ventilation
    Primary Outcome Measure Information:
    Title
    Survival
    Description
    All deaths occurred within 30 days of enrollment
    Time Frame
    Hospital stay (time until death): participants will be followed for the duration of hospital stay, an expected average of 30 days).
    Secondary Outcome Measure Information:
    Title
    Hospital days
    Time Frame
    up to hospital discharge, approximately 30 days
    Title
    ICU days
    Time Frame
    up to ICU discharge, approximately 30 days
    Other Pre-specified Outcome Measures:
    Title
    Hospital costs
    Description
    $US
    Time Frame
    Hospital stay
    Title
    Bleeding/Hemorrhage
    Description
    Bleeding in ECCO2R subjects exceeded that in control subjects
    Time Frame
    Hospital stay

    10. Eligibility

    Sex
    All
    Minimum Age & Unit of Time
    18 Years
    Maximum Age & Unit of Time
    65 Years
    Accepts Healthy Volunteers
    No
    Eligibility Criteria
    Men and women with acute respiratory distress syndrome. Inclusion Criteria: ECMO ENTRY CRITERIA (PaO2 < 50 mm Hg -REPEATED THREE TIMES): Rapid entry: 2 hours at fraFIO2=1.00 and PEEP>5 cm H2O with PaCO2=30-45 mmHg Slow entry: 12 hours at fraction of inspired oxygen (FIO2)>0.60 and positive end-expiratory pressure (PEEP)>5 cm H2O with PaCO2=30-45 mmHg and right to Left shunt fraction >0.30 Exclusion Criteria: Contraindication to anti-coagulation (for example, gastrointestinal bleeding, recent cerebrovascular accident, or chronic bleeding disorder). Pw > 25 mm Hg (superseded by our screening criterion that Pw ~ 15 mm Hg). Mechanical ventilation >21. days. Severe chronic systemic disease or another clinical condition that, in itself,greatly limits survival; for example, Irreversible central nervous system disease Severe chronic pulmonary disease (forced expiratory volume in 1 second (FEV1)<1 L, FEV1/FVC(forced vital capacity) <0.3 of predicted, chronic PaCO2 >45 mm Hg, chest x-ray evidence of overinflation or interstitial infiltration, or previous hospitalization for chronic respiratory insufficiency) Total-body surface burns> 40% Rapidly fatal malignancy Chronic left ventricular failure Chronic renal failure (we required serum creatlnlne ~ 2 mg/dl or chronic dialysis therapy) Chronic liver failure (we required total serum bilirubin;?; 2 mg/dl) Immunosuppressed patients and patients with a positive human immu.. nodeficiency virus test

    12. IPD Sharing Statement

    Citations:
    PubMed Identifier
    3132189
    Citation
    Morris AH, Menlove RL, Rollins RJ, Wallace CJ, Beck E. A controlled clinical trial of a new 3-step therapy that includes extracorporeal CO2 removal for ARDS. ASAIO Trans. 1988 Jan-Mar;34(1):48-53. No abstract available.
    Results Reference
    background
    PubMed Identifier
    2684495
    Citation
    Sittig DF, Gardner RM, Pace NL, Morris AH, Beck E. Computerized management of patient care in a complex, controlled clinical trial in the intensive care unit. Comput Methods Programs Biomed. 1989 Oct-Nov;30(2-3):77-84. doi: 10.1016/0169-2607(89)90060-6.
    Results Reference
    background
    PubMed Identifier
    2776450
    Citation
    Sittig DF, Pace NL, Gardner RM, Beck E, Morris AH. Implementation of a computerized patient advice system using the HELP clinical information system. Comput Biomed Res. 1989 Oct;22(5):474-87. doi: 10.1016/0010-4809(89)90040-2.
    Results Reference
    background
    PubMed Identifier
    2250128
    Citation
    Sittig DF, Gardner RM, Morris AH, Wallace CJ. Clinical evaluation of computer-based respiratory care algorithms. Int J Clin Monit Comput. 1990 Jul;7(3):177-85. doi: 10.1007/BF02915583.
    Results Reference
    background
    PubMed Identifier
    2019184
    Citation
    Suchyta MR, Elliott CG, Colby T, Rasmusson BY, Morris AH, Jensen RL. Open lung biopsy does not correlate with pulmonary function after the adult respiratory distress syndrome. Chest. 1991 May;99(5):1232-7. doi: 10.1378/chest.99.5.1232.
    Results Reference
    background
    PubMed Identifier
    2009801
    Citation
    Suchyta MR, Clemmer TP, Orme JF Jr, Morris AH, Elliott CG. Increased survival of ARDS patients with severe hypoxemia (ECMO criteria). Chest. 1991 Apr;99(4):951-5. doi: 10.1378/chest.99.4.951.
    Results Reference
    background
    PubMed Identifier
    1820417
    Citation
    Henderson S, Crapo RO, Wallace CJ, East TD, Morris AH, Gardner RM. Performance of computerized protocols for the management of arterial oxygenation in an intensive care unit. Int J Clin Monit Comput. 1991-1992;8(4):271-80. doi: 10.1007/BF01739128.
    Results Reference
    background
    PubMed Identifier
    1820416
    Citation
    East TD, Morris AH, Wallace CJ, Clemmer TP, Orme JF Jr, Weaver LK, Henderson S, Sittig DF. A strategy for development of computerized critical care decision support systems. Int J Clin Monit Comput. 1991-1992;8(4):263-9. doi: 10.1007/BF01739127.
    Results Reference
    background
    PubMed Identifier
    1555423
    Citation
    Suchyta MR, Clemmer TP, Elliott CG, Orme JF Jr, Weaver LK. The adult respiratory distress syndrome. A report of survival and modifying factors. Chest. 1992 Apr;101(4):1074-9. doi: 10.1378/chest.101.4.1074.
    Results Reference
    background
    PubMed Identifier
    1541135
    Citation
    East TD, Bohm SH, Wallace CJ, Clemmer TP, Weaver LK, Orme JF Jr, Morris AH. A successful computerized protocol for clinical management of pressure control inverse ratio ventilation in ARDS patients. Chest. 1992 Mar;101(3):697-710. doi: 10.1378/chest.101.3.697.
    Results Reference
    background
    PubMed Identifier
    7949979
    Citation
    Morris AH, East TD, Wallace CJ, Orme J Jr, Clemmer T, Weaver L, Thomas F, Dean N, Pearl J, Rasmusson B. Ethical implications of standardization of ICU care with computerized protocols. Proc Annu Symp Comput Appl Med Care. 1994:501-5.
    Results Reference
    background
    PubMed Identifier
    7922426
    Citation
    Morris AH. Adult respiratory distress syndrome and new modes of mechanical ventilation: reducing the complications of high volume and high pressure. New Horiz. 1994 Feb;2(1):19-33.
    Results Reference
    background
    PubMed Identifier
    8201102
    Citation
    Morris AH. Uncertainty in the management of ARDS: lessons for the evaluation of a new therapy. Intensive Care Med. 1994;20(2):87-9. doi: 10.1007/BF01707658. No abstract available.
    Results Reference
    background
    PubMed Identifier
    8341851
    Citation
    Suchyta MR, Elliott CG, Jensen RL, Crapo RO. Predicting the presence of pulmonary function impairment in adult respiratory distress syndrome survivors. Respiration. 1993;60(2):103-8. doi: 10.1159/000196182.
    Results Reference
    background
    PubMed Identifier
    8087579
    Citation
    Morris AH. Protocol management of adult respiratory distress syndrome. New Horiz. 1993 Nov;1(4):593-602. Erratum In: New Horiz 1994 Feb;2(1):7.
    Results Reference
    background
    PubMed Identifier
    8306022
    Citation
    Morris AH, Wallace CJ, Menlove RL, Clemmer TP, Orme JF Jr, Weaver LK, Dean NC, Thomas F, East TD, Pace NL, Suchyta MR, Beck E, Bombino M, Sittig DF, Bohm S, Hoffmann B, Becks H, Butler S, Pearl J, Rasmusson B. Randomized clinical trial of pressure-controlled inverse ratio ventilation and extracorporeal CO2 removal for adult respiratory distress syndrome. Am J Respir Crit Care Med. 1994 Feb;149(2 Pt 1):295-305. doi: 10.1164/ajrccm.149.2.8306022. Erratum In: Am J Respir Crit Care Med 1994 Mar;149(3 Pt 1):838.
    Results Reference
    result
    PubMed Identifier
    7812567
    Citation
    Habashi NM, Reynolds HN, Borg U, Cowley RA. Randomized clinical trial of pressure-controlled inverse ration ventilation and extra corporeal CO2 removal for ARDS. Am J Respir Crit Care Med. 1995 Jan;151(1):255-6. doi: 10.1164/ajrccm.151.1.7812567. No abstract available.
    Results Reference
    result
    PubMed Identifier
    7697266
    Citation
    Brunet F, Mira JP, Dhainaut JF, Dall'ava-Santucci J. Efficacy of low-frequency positive-pressure ventilation-extracorporeal CO2 removal. Am J Respir Crit Care Med. 1995 Apr;151(4):1269-70. doi: 10.1164/ajrccm/151.4.1269-a. No abstract available.
    Results Reference
    result
    PubMed Identifier
    9310029
    Citation
    Falke KJ. Randomized clinical trial of pressure-controlled inverse ratio ventilation and extracorporeal CO2 removal for adult respiratory distress syndrome. Am J Respir Crit Care Med. 1997 Sep;156(3 Pt 1):1016-7. No abstract available.
    Results Reference
    result

    Learn more about this trial

    Extracorporeal Carbon Dioxide Removal for Acute Respiratory Distress Syndrome

    We'll reach out to this number within 24 hrs